UY36197A - Caracterización biológica de un producto farmacológico derivado de acetato de glatiramer mediante células de mamífero humano y no humano - Google Patents

Caracterización biológica de un producto farmacológico derivado de acetato de glatiramer mediante células de mamífero humano y no humano

Info

Publication number
UY36197A
UY36197A UY0001036197A UY36197A UY36197A UY 36197 A UY36197 A UY 36197A UY 0001036197 A UY0001036197 A UY 0001036197A UY 36197 A UY36197 A UY 36197A UY 36197 A UY36197 A UY 36197A
Authority
UY
Uruguay
Prior art keywords
human
glatiramer acetate
product derived
mammal cells
biological characterization
Prior art date
Application number
UY0001036197A
Other languages
English (en)
Inventor
Hayden Michael
Grossman Iris
Hasson Tal
Ladkani David
Fadi George Towfic
Sarah Elisabeth Kolitz
Benjamin James Zeskind
Hayardeny Liat
Original Assignee
Teva Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Teva Pharma filed Critical Teva Pharma
Publication of UY36197A publication Critical patent/UY36197A/es

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • G01N33/5023—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects on expression patterns
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Chemical & Material Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Toxicology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Food Science & Technology (AREA)
  • Cell Biology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

La presente invención provee un proceso de caracterización de una sustancia o producto farmacológico relacionado con acetato de glatiramer que comprende los pasos de: a) obtener un lote de la sustancia o producto farmacológico relacionado con acetato de glatiramer; b) poner en contacto células de mamífero con una cantidad de la sustancia o producto farmacológico relacionado con acetato de glatiramer del paso a); y c) determinar el nivel de expresión de al menos uno de los genes descritos en este documento, caracterizando así la sustancia o producto farmacológico relacionado con acetato de glatiramer del paso a).
UY0001036197A 2014-07-01 2015-06-29 Caracterización biológica de un producto farmacológico derivado de acetato de glatiramer mediante células de mamífero humano y no humano UY36197A (es)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201462019857P 2014-07-01 2014-07-01
US201462020358P 2014-07-02 2014-07-02
US201462025953P 2014-07-17 2014-07-17
US201462047437P 2014-09-08 2014-09-08
US201462078369P 2014-11-11 2014-11-11
US201562134245P 2015-03-17 2015-03-17
US201562162308P 2015-05-15 2015-05-15

Publications (1)

Publication Number Publication Date
UY36197A true UY36197A (es) 2016-01-29

Family

ID=55020098

Family Applications (1)

Application Number Title Priority Date Filing Date
UY0001036197A UY36197A (es) 2014-07-01 2015-06-29 Caracterización biológica de un producto farmacológico derivado de acetato de glatiramer mediante células de mamífero humano y no humano

Country Status (6)

Country Link
EP (1) EP3164710A4 (es)
CA (1) CA2952849A1 (es)
IL (1) IL249686A0 (es)
TW (1) TW201610169A (es)
UY (1) UY36197A (es)
WO (1) WO2016004250A2 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018053109A1 (en) * 2016-09-14 2018-03-22 Teva Pharmaceutical Industries Ltd. Gene expression characterization of a glatiramer acetate related drug product in mammalian and human cells
CN116637123B (zh) * 2023-06-07 2024-02-13 上海市东方医院（同济大学附属东方医院） 敲降或下调C15orf39基因表达的试剂在制备治疗胃癌的药物中的应用

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008157697A2 (en) * 2007-06-21 2008-12-24 Momenta Pharmaceuticals, Inc. Copolymer assay

Also Published As

Publication number Publication date
WO2016004250A3 (en) 2016-03-17
IL249686A0 (en) 2017-02-28
CA2952849A1 (en) 2016-01-07
TW201610169A (zh) 2016-03-16
WO2016004250A2 (en) 2016-01-07
EP3164710A4 (en) 2018-04-11
EP3164710A2 (en) 2017-05-10

Similar Documents

Publication Publication Date Title
PE20151980A1 (es) Caracterizacion de un medicamento relacionado con acetato de glatiramer
EA202090931A3 (ru) Композиции и способы перепрограммирования tcr с помощью гибридных белков
EA201890013A1 (ru) Способы получения tcr гамма дельтат-клеток
CO2017000507A2 (es) Receptor quimérico de antígeno bcma
MX2021008143A (es) Metodos para cosechar cultivos de celulas de mamifero.
EA202092987A2 (ru) Липид, содержащий докозапентаеновую кислоту
AR090973A1 (es) Anticuerpos utiles para el diagnostico del cancer
CY1122612T1 (el) Μεθοδος
CO2017006156A2 (es) Un método para manufacturar una proteina de interes, donde dicha proteina es expresada en una celula huesped
BR112016024494A2 (pt) análogos de peptídeo com sonda(s) de aminoácidos ramificados
UY36870A (es) Análogos de insulina novedosos
CO2017005773A2 (es) Composiciones, dispositivos, y métodos de pruebas de sensibilidad del ibs
EA201791275A1 (ru) Способы получения ctp-модифицированных полипептидов длительного действия
BR112016024895A2 (pt) fator secretório de proteína com alta eficácia secretória e um vetor de expressão compreendendo o mesmo
CL2016002632A1 (es) Sistema de calibracion de brazo
MX2015014892A (es) Metodo para un ensayo de deteccion de farmacos basado en celulas y el uso del mismo.
MX2022003399A (es) Metodo basado en celulas para determinar la potencia de la defibrotida.
MX2017001979A (es) Metodo y aparato in vitro para analizar el comportamiento de sustancias en ambiente fisiologico simulado.
MX2017014247A (es) Metodos para valorar la pureza de una preparacion de celulas germinales mesenquimales.
BR112018000168A2 (pt) método para produção de células ips de alta qualidade
UY36197A (es) Caracterización biológica de un producto farmacológico derivado de acetato de glatiramer mediante células de mamífero humano y no humano
WO2015121636A3 (en) Fuel source, fuel cell system and associated method
IN2014DN10790A (es)
WO2015068075A3 (en) Detection of tau
AR101088A1 (es) Caracterización biológica de un producto farmacológico derivado de acetato de glatiramer mediante células de mamífero humano y no humano

Legal Events

Date Code Title Description
109 Application deemed to be withdrawn

Effective date: 20220629